cemiplimab   Click here for help

GtoPdb Ligand ID: 10090

Synonyms: cemiplimab-rwlc | Libtayo® | REGN-2810 | REGN2810 | SAR-439684 | SAR439684
Approved drug Immunopharmacology Ligand
cemiplimab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Cemiplimab (REGN2810) is a fully human anti-PD-1 immuno-oncology biological therapeutic that was developed by Regeneron Pharmaceuticals [1-2]. This antibody was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [4].
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2018), EMA (2019))
International Nonproprietary Names Click here for help
INN number INN
10691 cemiplimab
Synonyms Click here for help
cemiplimab-rwlc | Libtayo® | REGN-2810 | REGN2810 | SAR-439684 | SAR439684
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 846
Reactome Drug Reactome logo R-ALL-9679434
Reactome Reaction Reactome logo R-HSA-9679421
Other databases
GtoPdb PubChem SID 381118800
Search PubMed clinical trials cemiplimab
Search PubMed titles cemiplimab
Search PubMed titles/abstracts cemiplimab